2023-11-15T12:09:59-06:00 2022-12-31 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2022-01-01 800631734 NEW YORK GENOME CENTER INC NEWY 6469777000 101 AVENUE OF THE AMERICAS FL 7 NEW YORK NY 100131941 MARIA JOANTA CHIEF FINANCIAL OFFICER 6469777000 2023-11-14 1 MARIA JOANTA 999009999 0 EVAN W SEEKAMP P01907071 2127589700 2023-11-14 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z TOM MANIATIS 101 AVE OF THE AMERICAS NEW YORK NY 10013 72179367 0 X WWW.NYGENOME.ORG X 2010 DE ADVANCING GENOMIC RESEARCH TO DRIVE NOVEL BIOMEDICAL DISCOVERIES TO IMPROVE HUMAN HEALTH. 24 23 240 25 1946211 0 61556925 53970524 9002608 11277968 27107 -12410 1712471 2665604 72299111 67901686 1760070 2253429 0 0 27400508 29302214 250 140 905356 39947593 40640090 69108421 72195873 3190690 -4294187 85222125 181740451 46079469 146891982 39142656 34848469 X OPERATE A STATE-OF-THE-ART, WORLD CLASS GENOMIC RESEARCH CENTER THAT CREATES AND USES ADVANCED GENOMICS TO UNDERSTAND THE GENETIC BASIS OF DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O. 0 0 53435617 2253429 9825238 GENOME SEQUENCING: NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST SEVEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 86,900 WHOLE GENOME SAMPLES. NYGC HAS FIVE NOVASEQ SYSTEMS SEQUENCERS, WITH THE CAPACITY TO SEQUENCE THOUSANDS OF GENOMES A YEAR. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. SEE SCHEDULE O. 5438939 1452730 CLINICAL SEQUENCING: NYGC IS AUTHORIZED BY THE NEW YORK STATE DEPARTMENT OF HEALTH TO OFFER THE FOLLOWING APPROVED CLINICAL TESTS THROUGH ITS CLEP/CLIA CERTIFIED CLINICAL LABORATORY: CONSTITUTIONAL WHOLE GENOME SEQUENCING FOR UNDIAGNOSED DISEASE, CONSTITUTIONAL WHOLEGENOME SEQUENCING FOR PREDISPOSITIONAL GENETIC SCREENING, ONCOLOGY WHOLE GENOME AND TRANSCRIPTOME SEQUENCING, CONSTITUTIONAL WHOLE EXOME SEQUENCING, TARGETED VARIANT TESTING USING SANGER SEQUENCING, ONCOLOGY WHOLE EXOME AND TRANSCRIPTOME SEQUENCING, AND THE SMASH GENOMIC ASSAY. 58874556 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 1 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 63 0 1 240 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 24 23 0 0 1 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT FL GA HI IL KS KY LA ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X NANCY KONG 6469777154 101 AVENUE OF THE AMERICAS 7TH FL NEW YORK NY 10013 X RUSSELL L CARSON MBA DIRECTOR & CHAIRMAN 1.00 0.00 X X 0 0 0 IVAN G SEIDENBERG MBA DIRECTOR & CO-CHAIR 1.00 0.00 X X 0 0 0 HERB PARDES MD DIRECTOR & EXEC. VICE CHAIR 1.00 0.00 X 0 0 0 GORDON F TOMASELLI MD DIRECTOR 1.00 0.00 X 0 0 0 BRUCE STILLMAN PHD DIRECTOR 1.00 0.00 X 0 0 0 ANIL RUSTGI MD DIRECTOR (THRU 03/22) 1.00 0.00 X 0 0 0 KATRINA ARMSTRONG MD DIRECTOR (AS OF 03/22) 1.00 0.00 X 0 0 0 CRAIG B THOMPSON MD DIRECTOR (THRU 10/22) 1.00 0.00 X 0 0 0 SELWYN VICKERS MD DIRECTOR (AS OF 10/22) 1.00 0.00 X 0 0 0 DENNIS S CHARNEY MD DIRECTOR 1.00 0.00 X 0 0 0 DAFNA BAR-SAGI PHD SENIOR VP, CHIEF SCIENTIFIC OFFICER 1.00 0.00 X 0 0 0 KEVIN J TRACEY MD DIRECTOR 1.00 0.00 X 0 0 0 KENNETH A DILL PHD DIRECTOR 1.00 0.00 X 0 0 0 RICHARD P LIFTON MD PHD DIRECTOR 1.00 0.00 X 0 0 0 AUGUSTINE M K CHOI MD DIRECTOR 1.00 0.00 X 0 0 0 ELI CASDIN DIRECTOR 1.00 0.00 X 0 0 0 NICHOLAS DONOFRIO DIRECTOR 1.00 0.00 X 0 0 0 JOSEPH E EDELMAN DIRECTOR 1.00 0.00 X 0 0 0 JOHN B EHRENKRANZ DIRECTOR 1.00 0.00 X 0 0 0 ANTHONY B EVNIN PHD DIRECTOR 1.00 0.00 X 0 0 0 JOHN P HAVENS DIRECTOR 1.00 0.00 X 0 0 0 WESLIE R JANEWAY DIRECTOR 1.00 0.00 X 0 0 0 FRANK V SICA DIRECTOR & COMMITTEE CHAIR 1.00 0.00 X 0 0 0 JIM SIMONS PHD DIRECTOR 1.00 0.00 X 0 0 0 NANCY THORNBERRY DIRECTOR (AS OF 10/22) 1.00 0.00 X 0 0 0 TOM MANIATIS PHD SCIENTIFIC DIRECTOR & CEO 40.00 0.00 X X 633696 0 0 ELIZABETH BROOKS O'BRIEN VP & GENERAL COUNSEL 40.00 0.00 X 453705 0 41087 MARIA JOANTA CHIEF FINANCIAL OFFICER 40.00 0.00 X 365440 0 47560 CAROL ASHE CHIEF BUSINESS OFFICER 40.00 0.00 X 425448 0 61483 CHARLES GAGNON CHIEF INFORMATION OFFICER 40.00 0.00 X 329980 0 47431 THOMAS LEHNER SCI DIR, NEURO DIS GEN 40.00 0.00 X 394617 0 38366 SOREN GERMER SVP, GENOME TECHNOLOGIES 40.00 0.00 X 424568 0 35406 MICHAEL CHARLES ZODY SCIENTIFIC DIR, COMP BIOLOGY 40.00 0.00 X 350538 0 27331 SARAH LESSER AVINS SVP, ADVANCEMENT & CHIEF DEV. OFC. 40.00 0.00 X 554010 0 18417 SHAILAJA GARGEYA SENIOR DIR, SOFTWARE ENGINEER 40.00 0.00 X 320347 0 18312 DAYNA M OSCHWALD CHIEF OF STAFF 40.00 0.00 X 268319 0 35681 CHRISTOPHER PHIFER BLACK SENIOR DIRECTOR, RESEARCH COMPUTING 40.00 0.00 X 244736 0 42798 HANNAH GOULDING SENIOR DIRECTOR, HUMAN RESOURCES 40.00 0.00 X 235875 0 14269 JESSICA LEIGH LEITNER SENIOR DIRECTOR, DEVELOPMENT 40.00 0.00 X 227847 0 21817 5229126 0 449958 79 0 1 0 DONNELLY MECHANICAL 96-59 222ND STREET QUEENS NY 11429 ENGINEERING SERVICES 758802 GUARDIAN SERVICES INDUSTRIES INC 88005 EXPEDITE WAY CHICAGO IL 60695 CLEANING SERVICES 365998 STONECOURT 365 HOLDINGS LLC 200 CONNECTICUT AVENUE SUITE 5A NORWALK CT 06854 DATA SERVICES 231313 KPMG LLP PO BOX 120511 DALLAS TX 75312 ACCOUNTING SERVICES 164350 WAYNE CLARKE 327 3D ST E SASKATOON SASKATCHEWAN CA S7H 1L4 CONSULTING SERVICES 149042 51 2735000 14946320 36289204 2153885 53970524 RESEARCH SEQUENCING 541700 9825238 7879027 1946211 CLINICAL SEQUENCING 541700 1452730 1452730 11277968 -12410 -12410 2073162 2073162 4115198 4277681 -162483 -162483 -162483 EDC LOAN RECOGNITION 900099 526245 526245 OTHER REVENUE 900099 228680 228680 754925 67901686 9331757 1946211 2653194 2148906 2148906 104523 104523 4231643 1883139 1776077 572427 19467399 14947954 4308872 210573 1191827 887950 271721 32156 2286655 1788690 491800 6165 2124690 1609600 499133 15957 293528 293528 164600 164600 60453 60453 140 140 2906160 2688760 217400 418019 102382 313992 1645 3039096 2654651 383161 1284 402373 402373 13493554 11382264 2075998 35292 276349 264043 12171 135 97094 77562 18295 1237 301313 165081 134958 1274 5179168 4834587 325700 18881 660470 660470 DIRECT COST OF SEQUENCI 10048800 10048800 RESEARCH 2755732 2755732 RECRUITMENT 74048 11862 62186 469333 115697 345446 8190 72195873 58874556 12415961 905356 10264308 15599937 7859130 8022270 6350857 5451902 2423898 2260088 3304280 3583624 134621258 90760203 47467089 43861055 7552563 102961575 85222125 181740451 5032047 7934093 12695217 15840681 4100000 3380000 24252205 119737208 46079469 146891982 X 26513021 22710365 12629635 12138104 39142656 34848469 85222125 181740451 -4294187 0 X 0 1 X 1 1 1 X 115038771 32878926 51639109 61556925 53970524 315084255 115038771 32878926 51639109 61556925 53970524 315084255 143965935 171118320 2090669 3205975 3312682 4952174 5045294 18606794 104653 38049 742082 258491 19731 1163006 334854055 51336909 0.51100 0.49720 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 0 0 1 52663 52663 0 PART II-B, LINE 1: THROUGH ITS LEGISLATIVE CONSULTANTS, NYGC ADVOCATES FOR GOVERNMENT FUNDS TO SUPPORT CURRENT OPERATIONS AND/OR EXPAND RESEARCH OPPORTUNITIES AT NYGC. IN 2022, NYGC ENGAGED PAID LEGISLATIVE CONSULTANTS TO REPRESENT ITS INTERESTS AT THE STATE LEVEL. ADDITIONALLY, FROM TIME TO TIME, NYGC STAFF MAY CONTACT MEMBERS OF THE STATE LEGISLATURE AND EXECUTIVE BRANCH TO ENCOURAGE THEIR SUPPORT FOR NYGC. SUCH CONTACT MAY INCLUDE MEETINGS AND CORRESPONDENCE WITH PUBLIC OFFICIALS. THE APPROXIMATE COST ASSOCIATED WITH THESE ACTIVITIES IN 2022 WAS 21,172. NYGC ALSO MAINTAINS MEMBERSHIPS IN IRC SECTION 501(C)(6) ORGANIZATIONS THAT REPRESENT THE INTERESTS OF THE ACADEMIC MEDICAL RESEARCH COMMUNITY. IN 2022, $2,410 OF THE DUES THAT NYGC PAID TO THESE ASSOCIATIONS WERE ATTRIBUTABLE TO LOBBYING. 71120415 30385592 40734823 60212140 57302808 2909332 3288703 3071803 216900 43861055 SECURITY DEPOSITS 6435369 DEFERRED COMPENSATION 217995 OPERATING RIGHT OF USE ASSET 96308211 102961575 RIGHT OF USE LIABILITY 119737208 119737208 X 72179367 0 72179367 -4277681 -4277681 67901686 76473554 4277681 4277681 72195873 0 72195873 PART X, LINE 2: NYGC IS SUBJECT TO THE PROVISIONS OF THE FASB ASC SECTION 740-10-05, INCOME TAXES - OVERALL, RELATING TO ACCOUNTING AND REPORTING FOR UNCERTAINTY IN INCOME TAXES. NYGC RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED AND HAS DETERMINED IT DID NOT HAVE ANY EXPOSURE TO UNCERTAIN TAX POSITIONS DURING 2022 AND 2021. PART XI, LINE 4B - OTHER ADJUSTMENTS: RECLASS OF DIRECT RENTAL EXPENSE -4,277,681. PART XII, LINE 2D - OTHER ADJUSTMENTS: RECLASS OF DIRECT RENTAL EXPENSE 4,277,681. 1 EUROPE (INCLUDING ICELAND AND GREENLAND) 0 9 PROGRAM SERVICES RESEARCH 395914 NORTH AMERICA 0 3 PROGRAM SERVICES RESEARCH 237145 EAST ASIA AND THE PACIFIC 0 1 PROGRAM SERVICES RESEARCH 499 0 13 0 0 0 13 633558 0 633558 EUROPE (INCLUDING ICELAND AND GREENLAND) RESEARCH SUBAWARD 16760 WIRE 0 1 RESEARCH NORTH AMERICA 1 87763 WIRE 0 0 0 0 0 0 PART I, LINE 2: NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. PART I, LINE 3: THE PROGRAM EXPENDITURES ARE REPORTED ON THE ACCRUAL METHOD. PART III ACCOUNTING METHOD: 1 COLUMBIA UNIVERSITY 615 WEST 131ST STREET NEW YORK NY 10027 135598093 501(C)(3) 359184 0 RESEARCH SUBAWARD JOHNS HOPKIN UNIVERSITY 3910 KESWICK ROAD BALTIMORE MD 21211 520595110 501(C)(3) 258161 0 RESEARCH SUBAWARD MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 246134 0 RESEARCH SUBAWARD WEILL CORNELL MEDICAL COLLEGE 1300 YORK AVENUE NEW YORK NY 10065 150532082 501(C)(3) 212435 0 RESEARCH SUBAWARD NEW YORK UNIVERSITY 105 E 17TH STREET NEW YORK NY 10003 135562309 501(C)(3) 199783 0 RESEARCH SUBAWARD YALE UNIVERSITY PO BOX 208356 NEW HAVEN CT 06520 060646973 501(C)(3) 172656 0 RESEARCH SUBAWARD BROWN UNIVERSITY PO BOX 1929 PROVIDENCE RI 02912 050258809 501(C)(3) 168646 0 RESEARCH SUBAWARD COLD SPRING HARBOR LABORATORY ONE BUNGTOWN ROAD COLD SPRING HARBOR NY 11724 112013303 501(C)(3) 134783 0 RESEARCH SUBAWARD EUROPEAN MOLECULAR BIOLOGY LABORATORY 1 GUSTAVE L LEVY PL NEW YORK NY 10029 981291296 501(C)(3) 110920 0 RESEARCH SUBAWARD ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501(C)(3) 86216 0 RESEARCH SUBAWARD NYU SCHOOL OF MEDICINE 105 E 17TH STREET NEW YORK NY 10003 135562308 501(C)(3) 85610 0 RESEARCH SUBAWARD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 44299 0 RESEARCH SUBAWARD THE REGENTS OF THE UNIVERISTY OF CALIFORNIA 9500 GILMAN DRIVE MC LA JOLLA CA 920930009 943067788 501(C)(3) 30000 0 RESEARCH SUBAWARD 13 PART I, LINE 2: NYGC MONITORS THE USE OF GRANT FUNDS FOLLOWING THE UNIFORM GUIDANCE FOR FEDERAL AWARDS. GRANT RECIPIENTS ARE REQUIRED TO PROVIDE PROGRESS REPORTS. COSTS ARE REVIEWED FOR ALLOWABILITY WITH REGARD TO RELEVANT COST PRINCIPLES, BUDGETARY RESTRICTIONS, AND TERMS AND CONDITIONS OF THE AWARD BEFORE PAYMENT. 1 X X 0 0 0 0 0 0 0 0 0 TOM MANIATIS PHD SCIENTIFIC DIRECTOR & CEO 633696 0 0 0 0 0 0 0 0 0 633696 0 0 0 SARAH LESSER AVINS SVP, ADVANCEMENT & CHIEF DEV. OFC. 554010 0 0 0 0 0 18300 0 117 0 572427 0 0 0 ELIZABETH BROOKS O'BRIEN VP & GENERAL COUNSEL 453705 0 0 0 0 0 18300 0 22787 0 494792 0 0 0 CAROL ASHE CHIEF BUSINESS OFFICER 425448 0 0 0 0 0 61366 0 117 0 486931 0 0 0 SOREN GERMER SVP, GENOME TECHNOLOGIES 424568 0 0 0 0 0 18300 0 17106 0 459974 0 0 0 THOMAS LEHNER SCI DIR, NEURO DIS GEN 394617 0 0 0 0 0 25525 0 12841 0 432983 0 0 0 MARIA JOANTA CHIEF FINANCIAL OFFICER 365440 0 0 0 0 0 18300 0 29260 0 413000 0 0 0 MICHAEL CHARLES ZODY SCIENTIFIC DIR, COMP BIOLOGY 350538 0 0 0 0 0 18300 0 9031 0 377869 0 0 0 CHARLES GAGNON CHIEF INFORMATION OFFICER 326038 0 0 0 3942 0 16981 0 30450 0 377411 0 0 0 SHAILAJA GARGEYA SENIOR DIR, SOFTWARE ENGINEER 320347 0 0 0 0 0 18195 0 117 0 338659 0 0 0 DAYNA M OSCHWALD CHIEF OF STAFF 268319 0 0 0 0 0 15825 0 19856 0 304000 0 0 0 CHRISTOPHER PHIFER BLACK SENIOR DIRECTOR, RESEARCH COMPUTING 244736 0 0 0 0 0 15098 0 27700 0 287534 0 0 0 HANNAH GOULDING SENIOR DIRECTOR, HUMAN RESOURCES 235875 0 0 0 0 0 14152 0 117 0 250144 0 0 0 JESSICA LEIGH LEITNER SENIOR DIRECTOR, DEVELOPMENT 227847 0 0 0 0 0 13739 0 8078 0 249664 0 0 0 PART I, LINE 3 IN 2022, NYGC'S SCIENTIFIC DIRECTOR & CEO WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR & CEO, AN OFFICER OF THE CORPORATION AND AS A SENIOR ASSOCIATE MEMBER OF NYGC'S FACULTY. HE OVERSAW NYGC'S RESEARCH PROGRAM AND UNDERTOOK OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. THE SCIENTIFIC DIRECTOR & CEO DEVOTED 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS. IN 2022, NYGC HIRED AN INDEPENDENT COMPENSATION CONSULTANT TO PERFORM AN EXECUTIVE TOTAL COMPENSATION STUDY OF SENIOR MANAGEMENT'S COMPENSATION, INCLUDING THE SCIENTIFIC DIRECTOR & CEO. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO ALL MEMBERS OF SENIOR MANAGEMENT, INCLUDING THE SCIENTIFIC DIRECTOR & CEO, WAS REASONABLE. SILAS MANIATIS FAMILY MEMBER 195148 SALARY+BENEFITS 0 X RESEARCH SUPPLIES 199 2153885 FMV 0 0 0 PART I, COLUMN (B): THE NUMBER REPORTED IN PART I, COLUMN B REPRESENTS THE NUMBER OF UNITS CONTRIBUTED. FORM 990, PART I, LINE 1 & PART III, LINE 1: THE NEW YORK GENOME CENTER (NYGC) IS AN INDEPENDENT NON-PROFIT SCIENTIFIC RESEARCH INSTITUTION DEDICATED TO COLLABORATIVE GENETIC AND GENOMIC RESEARCH. NYGC'S MISSION IS TO ADVANCE GENOMIC SCIENCE, AND THROUGH ITS APPLICATION, TO DRIVE NOVEL BIOMEDICAL DISCOVERIES. NYGC'S AREAS OF FOCUS INCLUDE THE DEVELOPMENT OF COMPUTATIONAL AND EXPERIMENTAL GENOMIC METHODS AND DISEASE-FOCUSED RESEARCH TO BETTER UNDERSTAND THE GENETIC BASIS OF CANCER, NEURODEGENERATIVE DISEASE AND NEUROPSYCHIATRIC DISEASE. THE NYGC TEAM, LED BY EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO TOM MANIATIS, PHD, INCLUDES ASSOCIATE AND CORE FACULTY MEMBERS WHO HOLD JOINT APPOINTMENTS AT LEADING ACADEMIC INSTITUTIONS. THE CENTER BRINGS TOGETHER OUTSTANDING THOUGHT LEADERS FROM ELEVEN INSTITUTIONAL FOUNDING MEMBERS, SIX ASSOCIATE MEMBER INSTITUTIONS, AND 87 AFFILIATE SCIENTIFIC MEMBERS TO ENGAGE IN COLLABORATIVE RESEARCH. CONVENING TALENT AND EXPERTISE FROM MULTIPLE TOP-TIER SCIENTIFIC AND MEDICAL INSTITUTIONS IN THE NEW YORK AREA AND BEYOND, WE HAVE CREATED A HIGHLY COLLABORATIVE SCIENTIFIC ECOSYSTEM AND COMMUNITY RESOURCE THAT IS MORE THAN THE SUM OF ITS PARTS. NYGC ALSO PROVIDES RESEARCHERS WITH ACCESS TO STATE-OF-THE-ART GENOMIC INFRASTRUCTURE (E.G., COMPUTER HARDWARE AND SOFTWARE, SEQUENCING INSTRUMENTS) AND TECHNOLOGY INNOVATION AND EXPERTISE. NYGC HAS THE FOLLOWING KEY OBJECTIVES: (I) LEADING AND CONTRIBUTING TO INTELLECTUALLY VIBRANT RESEARCH COLLABORATIONS IN THE ACADEMIC AND SCIENTIFIC COMMUNITY IN NEW YORK CITY, ACROSS THE COUNTRY AND AROUND THE WORLD. (II) RECRUITING AND RETAINING DIVERSE WORLD-CLASS SCIENTIFIC TALENT TO LEAD THE ORGANIZATION'S RESEARCH AND TECHNOLOGY DEVELOPMENT PROGRAMS; (III) SUPPORTING RESEARCH CONDUCTED BY THE INSTITUTIONAL FOUNDING MEMBERS, OTHER ACADEMIC, RESEARCH AND MEDICAL INSTITUTIONS AND THE BIOTECHNOLOGY/PHARMACEUTICAL INDUSTRY TO ADVANCE NYGC'S SCIENTIFIC RESEARCH MISSION; (IV) DEVELOPING INNOVATIVE EXPERIMENTAL AND COMPUTATIONAL GENOMIC METHODS BASED UPON THE RESEARCH AND SEQUENCING ACTIVITIES CONDUCTED AT THE ORGANIZATION'S FACILITY, FOR THE BROADER BENEFIT OF THE RESEARCH COMMUNITY; (V) IMPROVING HUMAN HEALTH THROUGH GENOMIC RESEARCH THAT DRIVES NOVEL BIOMEDICAL DISCOVERIES; (VI) STRIVING TO MAXIMIZE THE BENEFITS OF OUR RESEARCH AND INNOVATION FOR DIVERSE COMMUNITIES; (VII) PROVIDING TRAINING TO THE ACADEMIC, RESEARCH AND TECHNOLOGY COMMUNITIES; (VIII) CREATING A WORKPLACE ENVIRONMENT THAT IS WELCOMING AND FAIR TO ALL REGARDLESS OF RACE, ETHNICITY, GENDER, SEXUAL ORIENTATION, PHYSICAL DISABILITY, AGE, OR RELIGION, AND (IX) CONDUCTING ACTIVITIES ANCILLARY TO THESE OBJECTIVES. NYGC STRIVES TO CHAMPION DIVERSITY, EQUITY, AND INCLUSION IN ITS WORKPLACE AND IN THE APPLICATION OF ITS RESEARCH TO CLINICAL CARE. A FUNDAMENTAL GOAL OF THE GENOME CENTER IS ADDRESSING THE LACK OF DIVERSITY WITHIN DATA, SAMPLES, AND SUBJECTS IN GENOMICS RESEARCH. NYGC IS ALSO COMMITTED TO DIVERSITY ON THE CENTER'S BOARD OF DIRECTORS AND WITHIN ITS FACULTY, STAFF, AND SCIENTIFIC RESEARCHERS. FORM 990, PART III, LINE 4A & LINE 4B THE NEW YORK GENOME CENTER (NYGC) IS COMMITTED TO ADVANCING GENOMIC SCIENCE, AND THROUGH ITS APPLICATION, TO DRIVING THE DEVELOPMENT OF NOVEL BIOMEDICAL THERAPEUTICS FOR CLINICAL CARE. RESEARCH AND FACULTY CENTRAL TO THE SUCCESS OF NYGC IS OUR TALENTED FACULTY WHO POSE FUNDAMENTAL QUESTIONS, DEVELOP NOVEL APPROACHES TO SCIENTIFIC INQUIRY, AND DEEPLY PROBE THE BIOLOGICAL MECHANISMS RELEVANT TO HUMAN HEALTH AND DISEASE. THE GENOMIC EXPERTISE OF OUR WORLD-CLASS SCIENTISTS INCLUDES CANCER, NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISEASE, GENOME EDITING, SINGLE-CELL AND SPATIALLY-RESOLVED MULTIOMICS, HIGH-RESOLUTION IMAGING, 3-DIMENSIONAL GENOME STRUCTURE, FUNCTIONAL GENOMICS, WHOLE GENOME SEQUENCING, BIOINFORMATICS, COMPUTATIONAL BIOLOGY, MACHINE LEARNING, GENOMIC DATA PRIVACY, AND MOLECULAR DIAGNOSTICS. IN 2022, WE INCREASED THE SIZE AND BROADENED THE EXPERTISE OF OUR FACULTY, A STRATEGIC STEP FORWARD. WITH THESE NEW APPOINTMENTS, WE ADDED DEPTH, BREADTH, AND SCOPE TO THE GENOME CENTER'S OVERALL RESEARCH PROGRAM. THE NEW MEMBERS INCLUDE: - GAMZE GRSOY, PHD., AN EXPERT IN THE DEVELOPMENT AND APPLICATION OF NOVEL TOOLS FOR PRESERVING PRIVACY IN LARGE GENOMIC DATASETS AS WELL AS THE RELATIONSHIP BETWEEN GENOMES AND MOLECULAR MEASUREMENTS IN RELATION TO DISEASES - SANJA VICKOVI, PHD, AN ACCOMPLISHED TECHNOLOGIST AND ENGINEER FOCUSED ON DEVELOPING NOVEL TOOLS FOR SPATIAL GENOMICS - CHENXU ZHU, PHD, A DEVELOPER OF INNOVATIVE MULTIMODAL SINGLE-CELL GENOMIC TOOLS - TARJINDER SINGH, PHD, WHO JOINED US AS AN ASSOCIATE FACULTY MEMBER, IS A NEUROPSYCHIATRIC DISEASE RESEARCHER FOCUSED ON IDENTIFYING GENOMIC MARKERS THAT UNDERLIE THE CAUSES OF PSYCHIATRIC DISEASE. IN 2022, NYGC SCIENTISTS MADE CONTINUING CONTRIBUTIONS TO PIONEERING RESEARCH INCLUDING: - NYGC CORE FACULTY MEMBER NEVILLE SANJANA, PHD, WHO HOLDS A JOINT APPOINTMENT AT NEW YORK UNIVERSITY (NYU) AS AN ASSOCIATE PROFESSOR OF BIOLOGY WITH TENURE, DISCOVERED SYNTHETIC GENE PROGRAMS THAT PROFOUNDLY REWIRE T CELLS, MAKING THEM MORE EFFECTIVE AT FINDING AND FIGHTING CANCER CELLS. THE GOAL OF THIS LARGE-SCALE GENETIC SCREEN WAS TO IDENTIFY PRECISELY THOSE GENES THAT ENABLE T CELLS TO PROLIFERATE AND TO UNDERSTAND HOW THOSE GENES IMPACT OTHER ASPECTS OF IMMUNE CELL FUNCTION RELEVANT TO FIGHTING CANCER. - NYGC'S SCIENTIFIC DIRECTOR FOR COMPUTATIONAL BIOLOGY, MICHAEL ZODY, PHD, AND HIS TEAM, IN COLLABORATION WITH GROUPS AT THE MASSACHUSETTS GENERAL HOSPITAL, YALE UNIVERSITY, AND THE HUMAN GENOME STRUCTURAL VARIATION CONSORTIUM (HGSVC), EXPANDED THE 1000 GENOMES PROJECT (1KGP) RESOURCE TO INCLUDE NEARLY ALL PARENT-CHILD TRIOS IN THE COLLECTION, ALONGSIDE THE ORIGINAL SAMPLES, AND SEQUENCED THEM AT HIGH COVERAGE USING ILLUMINA NOVASEQ INSTRUMENTS. THE STUDY, PRESENTS COMPREHENSIVE ANALYSES OF THE HIGH-COVERAGE WHOLE GENOME SEQUENCING DATA ON THE EXPANDED 1KGP COHORT WHICH NOW CONSISTS OF 3,202 SAMPLES, INCLUDING 602 TRIOS. - DAVID KNOWLES, PHD, WHO HOLDS A JOINT APPOINTMENT AT COLUMBIA UNIVERSITY, IN COLLABORATION WITH INVESTIGATORS AT THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, RECEIVED AN AWARD IN THE AMOUNT OF $2.7M FROM THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) ENTITLED "DELINEATING THE NETWORK EFFECTS OF MENTAL DISORDER-ASSOCIATED VARIANTS USING CONVEX OPTIMIZATION METHODS". THE AIM OF THIS GRANT IS TO DEVELOP A SUITE OF NOVEL COMPUTATIONAL METHODS TO DETERMINE THE SHARED AND DISTINCT GENETIC COMPONENTS OF NEUROPSYCHIATRIC DISORDERS, INFER THE CAUSAL GENE NETWORKS UNDERLYING THESE COMPONENTS, AND MODEL HOW COMMON AND RARE GENETIC VARIANTS DISRUPT THESE NETWORKS. - CORE FACULTY MEMBER, MARCIN IMIELISKI, MD, PHD, WHO HOLDS A JOINT APPOINTMENT AT WEILL CORNELL MEDICINE, COLLABORATED WITH OXFORD NANOPORE TECHNOLOGIES TO DEVELOP A NEW METHOD OF ASSESSING THE THREE-DIMENSIONAL STRUCTURE OF THE HUMAN GENOME, OR HOW THE GENOME FOLDS, ON A LARGE SCALE. - NYGC'S CATHERINE REEVES, GIUSEPPE NARZISI, PHD, SOREN GERMER, PHD, MELISSA MARTON, NICOLAS ROBINE, PHD, LARA WINTERKORN, CHARLES GAGNON, AND MINITA SHAH RECEIVED AN AWARD IN THE AMOUNT OF $2.17M FROM THE NATIONAL CANCER INSTITUTE TO OPERATE A GENOMIC CHARACTERIZATION CENTER FOR TWO NEW STUDIES INVESTIGATING ENDOMETRIAL CANCER AND NASOPHARYNGEAL CARCINOMA, PROVIDING EXCEPTIONALLY HIGH QUALITY, COMPREHENSIVE, AND TIMELY GENOME-WIDE CHARACTERIZATION OF NUCLEIC ACID SAMPLES OBTAINED FROM CANCER PATIENTS IN ORDER TO IDENTIFY AND PROVIDE ANNOTATION FOR GENOMIC ALTERATIONS. - GAMZE GRSOY, PHD, WHO HOLDS A JOINT APPOINTMENT AT COLUMBIA UNIVERSITY, RECEIVED THE R35 MAXIMIZING INVESTIGATORS' RESEARCH AWARD FROM THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES FOR A PROJECT ENTITLED "TOOLS TO ADDRESS THE CHALLENGES OF PRESERVING PRIVACY IN SHARING AND ANALYSIS OF BIOMEDICAL DATA." THE GOAL OF THIS PROJECT IS TO QUANTIFY PRIVATE INFORMATION LEAKAGES FROM VARIOUS TYPES OF HUMAN-DERIVED BIOLOGICAL DATA AND TO DEVELOP PRIVACY-ENHANCING ANALYSIS SOFTWARE FOR DATA AT VARIOUS MOLECULAR LEVELS (GENOMICS, TRANSCRIPTOMICS, PHENOTYPE, AND CLINICAL DATA) AT SCALE. - CHENXU ZHU, PHD, WHO HOLDS A JOINT APPOINTMENT AT WEILL CORNELL MEDICINE, RECEIVED AN AWARD IN THE AMOUNT OF $513,842 FROM THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE TO FURTHER EXPAND THE SCALABILITY AND SPECTRUM FOR SINGLE CELL MULTI-MODAL GENOMIC ANALYSIS AND APPLY THESE TOOLS IN THE STUDY OF THE FUNCTION AND RELATIONSHIPS OF MULTIPLE REGULATORY LAYERS DURING MAMMALIAN DEVELOPMENT PROCESSES. - HEMALI PHATNANI, PHD, WHO HOLDS A JOINT APPOINTMENT AT COLUMBIA UNIVERSITY, RECEIVED AN AWARD FROM TARGET ALS FOR A PROJECT ON "SCALABLE PHENOTYPING OF ALS-ASSOCIATED POINT MUTATIONS, USING BASE EDITOR POOLED GENOMIC SCREENS AND A SINGLE CELL TRANSCRIPTOMIC READOUT." THE GOAL IS TO GENERATE DATA USING THE 4I PLATFORM THAT WILL EXTEND SPATIALLY RESOLVED TRANSCRIPTOME ANALYSES FOR AN UNBIASED, GENOME-WIDE VIEW OF CELL TYPE DEPENDENT CHANGES OVER THE COURSE OF DISEASE. - VAIDEHI JOBANPUTRA, PHD, FACMG, CHIEF DIAGNOSTICS OFFICER AT NYGC, PARTICIPATED IN A PANEL ON THE IMPLEMENTATION OF WHOLE-GENOME AND TRANSCRIPTOME SEQUENCING (WGTS) IN ROUTINE CANCER CARE AND DIAGNOSTICS. SHE JOINED TWENTY-FOUR GLOBAL EXPERTS IN ONCOLOGY, PATHOLOGY, GENETICS, TRANSLATIONAL RESEARCH, AND HEALTH TECHNOLOGY ASSESSMENT TO DISCUSS GENERAL AND TECHNICAL ASPECTS, HEALTH ECONOMICS AND REIMBURSEMENT, AND CLINICAL EVIDENCE NEEDS, AS WELL AS DATA ANALYSIS AND INTERPRETATION IN RELATION TO WGTS. ADDITIONAL ACCOMPLISHMENTS IN 2022 INCLUDE: IN 2022, NYGC MADE GREAT PROGRESS IN CORE RESEARCH AREAS UNDER THE LEADERSHIP OF THE NEW YORK GENOME CENTER'S EVNIN FAMILY SCIENTIFIC DIRECTOR AND CEO, TOM MANIATIS, PHD. NYGC FACULTY AND SCIENTIFIC STAFF PUBLISHED 46 STUDIES IN HIGH-IMPACT SCIENTIFIC JOURNALS THAT PROVIDED NEW GENOMIC APPROACHES AND TECHNOLOGIES AS WELL AS INSIGHTS INTO THE GENOMICS OF BIOLOGY AND DISEASE. NYGC RESEARCHERS HAVE DEVELOPED MANY INNOVATIVE GENOMIC TECHNOLOGIES AND NEW COMPUTATIONAL APPROACHES THAT ARE SHARED AND BROADLY ADOPTED WITHIN THE SCIENTIFIC COMMUNITY. CANCER: THE MACMILLAN FAMILY FOUNDATION, A FIRST-TIME DONOR MADE A SIGNIFICANT INVESTMENT IN 2022 TO CREATE THE MACMILLAN CENTER FOR THE STUDY OF THE NON-CODING CANCER GENOME. HIGHLIGHTING THE CENTER'S EXPERIENCE AND CAPACITY FOR COLLABORATION, OUR RESEARCHERS PROPOSED A BOLD SCIENTIFIC VISION FOCUSED ON UNDERSTANDING THE ROLE AND FUNCTION OF THE NON-CODING GENOME AND EPIGENOME IN CANCER EVOLUTION, PROGRESSION, AND TREATMENT RESPONSE. THE GENOME CENTER CANCER GROUP (GCCG), LED BY NOBEL LAUREATE HAROLD VARMUS, MD, NYGC AND WEILL CORNELL MEDICINE, AND HHMI INVESTIGATOR CHARLES SAWYERS, MD, MEMORIAL SLOAN KETTERING CANCER CENTER, IS COMPOSED OF CLINICIANS AND CANCER RESEARCHERS FROM NYGC'S MEMBER INSTITUTIONS, INCLUDING 10 NCI-DESIGNATED CANCER CENTERS. NYGC'S COLLABORATIVE CANCER INITIATIVE, POLYETHNIC-1000 (P-1000), WAS LAUNCHED IN 2018 TO ADVANCE CANCER GENOMICS IN UNDERREPRESENTED POPULATIONS. IN THE PAST YEAR, MELISSA B. DAVIS, PHD, ETHNICITY AND CANCER SCHOLAR FOR THE P-1000 INITIATIVE AND ASSOCIATE PROFESSOR OF CELL AND DEVELOPMENTAL BIOLOGY RESEARCH IN SURGERY AND DIRECTOR OF HEALTH EQUITY IN THE ENGLANDER INSTITUTE FOR PRECISION MEDICINE AT WEILL CORNELL MEDICINE PUBLISHED A STUDY ON THE BIOLOGICAL LINKS BETWEEN AFRICAN ANCESTRY AND DISEASE PROCESSES THAT AFFECT AN AGGRESSIVE CANCER TYPE CALLED TRIPLE-NEGATIVE BREAST CANCER (TNBC). THE RESEARCHERS' ANALYSIS OF TNBC TUMORS YIELDED A LARGE SET OF GENES WHOSE EXPRESSION DIFFERED IN PATIENTS WITH AFRICAN ANCESTRY COMPARED TO PATIENTS WITH EUROPEAN ANCESTRY. THE STUDY ALSO DESCRIBES DISTINCT PATTERNS OF IMMUNE RESPONSES IN PATIENTS WITH AFRICAN DESCENT THAT MAY EXPLAIN PATTERNS OF DISEASE PROGRESSION AND OUTCOMES, THUS ALTERING THE BENEFITS OF IMMUNOTHERAPIES. FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED) NEURODEGENERATIVE DISEASE: NYGC'S CENTER FOR GENOMICS OF NEURODEGENERATIVE DISEASE (CGND), LED BY DIRECTOR HEMALI PHATNANI, PHD, IS A GLOBAL COLLABORATION OF CLINICIANS, SCIENTISTS, GENETICISTS, AND COMPUTATIONAL BIOLOGISTS THAT CONTINUES TO MAKE GREAT STRIDES. THE NYGC ALS CONSORTIUM, LAUNCHED BY THE CGND IN 2016, IS DEDICATED TO THE GENERATION OF ONE OF THE LARGEST OPEN-SOURCE WHOLE GENOME SEQUENCING DATABASES OF ALS PATIENTS IN THE UNITED STATES. THIS CONSORTIUM HAS BROUGHT TOGETHER THE INTERNATIONAL ALS COMMUNITY, INCLUDING PROJECT ALS AND ANSWER ALS INITIATIVES, TO TAKE ADVANTAGE OF INTEGRATED DATASETS AND DEPLOY A WIDE ARRAY OF APPROACHES TO ALS RESEARCH WITH THE ULTIMATE GOAL OF UNDERSTANDING DISEASE PROGRESSION, IMPROVING DIAGNOSIS AND EARLY DETECTION, AND IDENTIFYING NEW TARGETS FOR THERAPEUTIC AND PREVENTATIVE INTERVENTIONS. THE WHOLE GENOME DATABASE WILL MERGE WITH A LARGE NIH DATABASE WITH OTHER TYPES OF GENOMIC DATA AND SERVE AS A LASTING RESOURCE FOR THE INTERNATIONAL ALS COMMUNITY, INCLUDING CONTINUED COLLABORATIVE RESEARCH THROUGH THE CONSORTIUM. NEUROPSYCHIATRIC DISEASE: DR. THOMAS LEHNER, NYGC'S SCIENTIFIC DIRECTOR FOR NEUROPSYCHIATRIC DISEASE, LEADS NYGC'S NEUROPSYCHIATRIC DISEASE SCIENTIFIC WORKING GROUP. ONE OF THE SIGNATURE INITIATIVES OF THIS GROUP IS GEMMA (GENOMIC MEDICINE FOR MENTAL HEALTH ADVANCEMENT), A NEW YORK STATE-WIDE PRECISION PSYCHIATRY COLLABORATION THAT AIMS TO INTEGRATE DIAGNOSTIC, DEMOGRAPHIC, AND MEDICAL RECORDS DATA WITH GENOMIC DATA TO CREATE A PLATFORM FOR SCIENTIFIC DISCOVERY, CLINICAL VALIDATION, AND TRANSLATIONAL IMPLEMENTATION. THIS RESOURCE WOULD IMPROVE THE QUALITY OF LIFE, SOCIAL EQUITY, AND OUTCOMES OF INDIVIDUALS WITH SERIOUS MENTAL ILLNESS IN NEW YORK. ADDITIONALLY, NYGC IS ADVANCING ITS CLINICAL OUTCOME PREDICTION OF PSYCHOSIS FROM EHRS (COPPER), A PILOT STUDY LEVERAGING THE GEMMA PLATFORM FOCUSED ON ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING, TO BUILD MODELS OF CLINICAL PREDICTORS OF DIAGNOSIS, TREATMENT, AND PROGNOSIS OF PSYCHOSIS-RELATED DISORDERS. IN PRECISION PSYCHIATRY, THE NYGC TEAM PLANS TO INTEGRATE LARGE-SCALE LONGITUDINAL ELECTRONIC HEALTH RECORDS, DIMENSIONAL PHENOTYPING, AND GENETIC ANALYSES TO IMPROVE CLINICAL PREDICTORS OF SERIOUS MENTAL ILLNESS. IN DECEMBER 2022, DR. LEHNER AND NEW ASSOCIATE FACULTY MEMBER, DR. TARJINDER SINGH, RECEIVED PHILANTHROPIC FUNDING TO LAUNCH A NEW PROJECT TO CARRY OUT WHOLE GENOME SEQUENCING AND BIOINFORMATIC ANALYSIS ON A WELL-CHARACTERIZED COHORT OF PATIENTS WITH SEVERE SCHIZOPHRENIA. IN A COLLABORATION WITH DR. CARLOS PATO AT RUTGERS UNIVERSITY AND LEVERAGING NEW REDUCED-COST SEQUENCING PLATFORMS, NYGC WILL SEQUENCE AND ANALYZE A COHORT OF 2,500 PATIENTS WITH SEVERE SCHIZOPHRENIA FROM THE RUTGERS GENOMIC PSYCHIATRY COHORT TO IDENTIFY POTENTIALLY CAUSATIVE GENETIC VARIANTS. RESEARCHERS WILL ALSO BE ABLE TO USE CELL LINES DERIVED FROM EACH PARTICIPANT IN THE COHORT TO INVESTIGATE THE UNDERLYING CAUSATIVE DISEASE MECHANISMS. THE RESEARCH TEAM PLANS TO INTEGRATE THE WHOLE GENOME SEQUENCE DATA WITH EXISTING LARGE-SCALE DATASETS, CONTROLS, AND INTERNATIONAL DISCOVERY EFFORTS TO ADVANCE PRECISION MEDICINE IN PSYCHIATRY. THIS YEAR, DRS. LEHNER AND SINGH ALONG WITH SCIENTIFIC DIRECTOR OF COMPUTATIONAL BIOLOGY, DR. MICHAEL ZODY, HAVE SUBMITTED A GRANT PROPOSAL IN COLLABORATION WITH THE BROAD INSTITUTE OF MIT AND HARVARD TO BREAKTHROUGH DISCOVERIES FOR THRIVING WITH BIPOLAR DISORDER (BD2) TO LAUNCH THE BIPOLAR DISORDER SEQUENCING AND GENE DISCOVERY INITIATIVE. THE PROJECT AIMS TO ASSEMBLE A SEQUENCED COHORT OF ~100,000 ANCESTRALLY DIVERSE INDIVIDUALS LIVING WITH BIPOLAR DISORDER (BD) WITH MATCHED CONTROL SAMPLES TO IDENTIFY RISK GENES FOR BD, UNCOVER THE BIOLOGICAL MECHANISMS UNDERLYING ITS PATHOBIOLOGY, AND CATALYZE THE DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES. GENOMIC TECHNOLOGY: THE NYGC TECHNOLOGY INNOVATION LAB HAS ESTABLISHED ITSELF AS A LEADER AT THE FOREFRONT OF GENOMIC SCIENCE AND TECHNOLOGY, CURRENTLY CENTERED ON THE INVENTION OF NEW CELLULAR, SUBCELLULAR AND SPATIALLY RESOLVED MEASUREMENT METHODS WITH IMPROVED THROUGHPUT, RESOLUTION, SENSITIVITY, ACCURACY, AND COST EFFICIENCY. MORE RECENTLY, THE LAB IS ALSO FOCUSED ON COMBINATIONS OF MEASUREMENTS IN THE SAME CELL SYSTEMS (OR "MULTIMODALITY") WITH ACCOMPANYING MATHEMATICAL AND STATISTICAL ADVANCES. THE INNOVATION LAB, UNDER THE LEADERSHIP OF SANJA VICKOVI, PHD AND IN COLLABORATION WITH NYGC FACULTY AS WELL AS OTHER ACADEMIC AND INDUSTRY PARTNERS, HAS CONTINUED TO DEVELOP AND APPLY GROUNDBREAKING GENOMIC TECHNOLOGIES IN THIS SPACE AND MAKING THEM BROADLY AVAILABLE TO THE SCIENTIFIC COMMUNITY. DR. VICKOVI IS AN EXPERIENCED AND ACCOMPLISHED ENGINEER WHO DEVELOPS TOOLS FOR SPATIAL GENOMICS THAT ENABLE PERTURBING HIGHLY COMPLEX INTERACTIONS IN HUMAN TISSUES, MANY OF WHICH ARE NOW COMMERCIALIZED. THE GENOME CENTER'S TECHNOLOGY INNOVATION LAB ALSO IS AN INTERNATIONALLY-RECOGNIZED PIONEER IN "SINGLE CELL" GENOMIC TECHNOLOGY,, AND COLLABORATES CLOSELY WITH NYGC CORE FACULTY MEMBER DR. RAHUL SATIJA TO DEVELOP COMPUTATIONAL TOOLS FOR DECODING SINGLE-CELL DATA WHICH HAVE "DEMOCRATIZED" SINGLE-CELL DATA ANALYSIS. THESE ADVANCES HAVE MADE IT POSSIBLE FOR SCIENTISTS WITH LITTLE MATHEMATICAL EXPERTISE TO TAKE ADVANTAGE OF SINGLE-CELL TECHNOLOGIES AND APPLY THEM TO A BROAD RANGE OF SCIENTIFIC INQUIRY. ADDITIONALLY, THE CENTER FOR INTEGRATED CELLULAR ANALYSIS (CICA): SINGLE CELL AND SPATIAL MULTI-OMICS, LED BY DR. SATIJA, REPRESENTS A COLLABORATIVE EFFORT BETWEEN TECHNOLOGY DEVELOPERS, COMPUTATIONAL BIOLOGISTS, NEUROSCIENTISTS, AND CANCER BIOLOGISTS FROM SEVEN NYC-BASED INSTITUTIONS TO DEVELOP TECHNOLOGIES FOR NOVEL SINGLE-CELL ANALYSES IN VARIOUS BIOLOGICAL CONTEXTS AND DISEASE STATES. CLINICAL LABORATORY: NYGC'S CLINICAL LABORATORY HAS LENT ITS INFRASTRUCTURE AND EXPERTISE TO SEVERAL LARGE-SCALE INITIATIVES IN CLINICAL GENOMICS, INCLUDING A COLLABORATION WITH WEILL CORNELL MEDICINE, NEWYORK-PRESBYTERIAN HOSPITAL, AND ILLUMINA ON A PRECISION MEDICINE COLLABORATION IN CANCER, CARDIOLOGY, ENDOCRINOLOGY, AND NEUROLOGY TO ASSESS AND IMPROVE THE VALUE OF CLINICAL WHOLE GENOMES WITH AIMS OF RETURNING CLINICALLY ACTIONABLE RESULTS, INTEGRATING ELECTRONIC HEALTH RECORDS, DEVELOPING NOVEL POLYGENIC RISK SCORES, AND GAINING A DEEPER UNDERSTANDING OF THE ROLE OF GENETICS IN THERAPEUTIC RESPONSES. FINALLY THE CLINICAL LABORATORY INITIATED A COLLABORATION WITH THE DEPARTMENT OF OBSTETRICS AND GYNECOLOGY AT COLUMBIA UNIVERSITY: THE WOMENS' GENETICS CENTER (WGC). THE WGC BUILDS ON THE COMBINED STRENGTH OF THE UNIVERSITY'S MATERNAL FETAL MEDICINE PHYSICIANS AND GENETIC COUNSELORS AND NYGC'S EXPERTISE IN TECHNOLOGY AND CLINICAL GENETICS TO DEVELOP AND APPLY NOVEL CLINICAL TESTS TO ADVANCE CARE FOR PREGNANT WOMEN. THE CLINICAL LABORATORY PERFORMED THE FIRST 15 WHOLE GENOME SEQUENCING PRENATAL TESTS TO DISCOVER THE GENETIC CAUSES OF ANOMALIES OBSERVED WITH ULTRASOUND, AND BEGAN PLANNING FOR THE DEVELOPMENT OF ADDITIONAL NOVEL CLINICALLY RELEVANT WHOLE GENOME BASED TESTS. RESEARCH SEQUENCING NYGC HAS ONE OF THE LARGEST VOLUME WHOLE GENOME SEQUENCING PROGRAMS IN NEW YORK. IN THE PAST SEVEN YEARS, NYGC'S SEQUENCING LABORATORY HAS SEQUENCED OVER 86,900 WHOLE GENOME SAMPLES. NYGC HAS FIVE NOVASEQ SYSTEMS SEQUENCERS, WITH THE CAPACITY TO SEQUENCE THOUSANDS OF GENOMES ANNUALLY. THIS STATE-OF-THE-ART SEQUENCING TECHNOLOGY ENABLES NYGC TO CONDUCT LARGE-SCALE GENOMICS PROJECTS WITH GREAT SPEED AND SAMPLE VOLUMES, AND TO EXPLORE THE GENOME IN MORE DEPTH WITH GREATER EFFICIENCY. NYGC'S RESEARCH SEQUENCING LAB, LED BY SOREN GERMER, PHD, SENIOR VICE PRESIDENT OF GENOME TECHNOLOGIES, PROCESSED MORE THAN 20,000 SAMPLES IN 2022, INCLUDING 7,640 WHOLE GENOME SEQUENCING SAMPLES (GERMLINE AND CANCER), 6,092 COVID VIRAL SAMPLES, AND 6,520 TRANSCRIPTOME (RNA) SEQUENCING SAMPLES. IN ADDITION THE LAB PERFORMED 14,082 RNA EXTRACTIONS, IN PART FOR OTHER LABORATORIES THAT EITHER DID NOT HAVE THE CAPACITY OR WERE NOT ABLE TO GENERATE RNA OF SUFFICIENT QUALITY. THE NYGC RESEARCH SEQUENCING LAB ALSO RECEIVED, TESTED AND OPERATIONALIZED THE TWO NEW SEQUENCING INSTRUMENTS PURCHASED IN 2021, AND BEGAN TO PROCESS SAMPLES FOR COLLABORATIVE PROJECTS USING THE INSTRUMENTS. ONE INSTRUMENT, FROM OXFORD NANOPORE TECHNOLOGIES, ADDS LONG READ CAPACITY TO THE CENTER'S SEQUENCING MENU, THE OTHER SEQUENCING INSTRUMENT, FROM ULTIMA GENOMICS,PROMISES SUBSTANTIALLY REDUCED REAGENT COSTS FOR HIGH-THROUGHPUT APPLICATIONS AND HAS CREATED A LOT OF EXCITEMENT IN THE GENOMICS COMMUNITY. FOR BOTH INSTRUMENTS, NYGC IS WORKING INTENSIVELY TO ENABLE THESE TECHNOLOGIES FOR A RANGE OF APPLICATIONS. FORM 990, PART III, LINE 4A & LINE 4B (CONTINUED) IN 2022, NYGC CONTINUED TO EXPAND ITS OPERATIONAL FOCUS ON SINGLE-CELL GENOMICS, MAKING AVAILABLE TO THE RESEARCH COMMUNITY THROUGH FUNCTIONAL GENOMIC COLLABORATIONS NEW CUTTING-EDGE TECHNIQUES INVENTED IN THE CENTER'S INNOVATION LAB. THESE INCLUDE CITE-SEQ, ASAP-SEQ, AND DOGMA-SEQ AS WELL AS THE 10X MULTIOME ASSAY, TECHNIQUES THAT ALLOW SIMULTANEOUS MEASUREMENT IN THOUSANDS OF CELLS COMBINATIONS OF CELL SURFACE PROTEIN MARKERS, RNA ABUNDANCE AND CHROMATIN ACCESSIBILITY. THE CENTER'S TECHNOLOGY INNOVATION LABORATORY HAS COMPLETED SEVERAL PROJECTS AND IS GEARING UP TO SUPPORT MULTIPLE LARGE GRANTS IN WHICH THESE ASSAYS WILL BE APPLIED. IN ADDITION, THE LAB HAS IMPLEMENTED A NOVEL AMPLIFICATION FREE SINGLE CELL WHOLE GENOME SEQUENCING ASSAY THAT IS BEING USED IN A LARGE STUDY OF ESOPHAGEAL CANCER IN A COLLABORATION WITH COLUMBIA UNIVERSITY AND CAMBRIDGE UNIVERSITY. DIVERSITY, EQUITY, AND INCLUSION IN 2020, NYGC LAUNCHED AN ORGANIZATION-WIDE DIVERSITY, EQUITY, AND INCLUSION ("DEI") INITIATIVE, AFFIRMING NYGC'S COMMITMENT TO TAKE ACTIONABLE STEPS TOWARD FOSTERING A COMMUNITY ENVIRONMENT THAT IS WELCOMING AND INCLUSIVE TO ALL. EACH EMPLOYEE HAS THE RIGHT TO BE TREATED WITH DIGNITY AND RESPECT OF INDIVIDUAL DIFFERENCES. IN 2022, NYGC'S CROSS-FUNCTIONAL DEI ADVISORY GROUP PROVIDED EDUCATION AND RESOURCES TO THE NYGC COMMUNITY TO RAISE AWARENESS OF DEI AND TO ENHANCE CULTURAL COMPETENCY, SUCH AS BOOK CLUBS, SHOWCASING THE WORK AND SKILLS OF A DIVERSE GROUP OF EMPLOYEES, STAFF, FACULTY AND TRAINEES, AND ORGANIZED DEI-RELATED EVENTS. THE CENTER ALSO BEGAN A SEARCH FOR A DIRECTOR OF DEI TO SPEARHEAD EXISTING AND EXPANDED DEI EFFORTS. FORM 990, PART VI, SECTION A, LINE 4 IN MARCH, 2022, NYGC'S BOARD OF DIRECTORS AMENDED THE CORPORATION'S BYLAWS TO DIVIDE THE BOARD'S INDEPENDENT MEMBERS INTO THREE GROUPS WITH STAGGERED TERMS. THE TERM OF ALL DIRECTORS IN A GIVEN GROUP NOW EXPIRES IN THE SAME YEAR, ELIMINATING THE NEED TO TRACK EACH DIRECTOR'S TERM ON AN INDIVIDUAL BASIS. IN ADDITION, THE BOARD APPROVED A SECOND AMENDMENT TO REDUCE THE BOARD'S STANDING COMMITTEES FROM SIX TO FOUR (EXECUTIVE, AUDIT, COMPENSATION, DEVELOPMENT AND NOMINATING). THE GOAL OF THIS CHANGE WAS TO BETTER ALIGN THE NUMBER OF STANDING COMMITTEES TO THE SIZE OF THE BOARD, ELIMINATE OVERLAPPING COMMITTEE RESPONSIBILITIES, AND ENHANCE THE OVERALL FUNCTIONALITY AND PRODUCTIVITY OF BOARD COMMITTEES. FORM 990, PART VI, SECTION A, LINE 6 ORGANIZATION MEMBERS AS OF DECEMBER 31, 2022, THE CENTER HAD A TOTAL OF 17 MEMBERS, CONSISTING OF 11 INSTITUTIONAL FOUNDING MEMBERS AND SIX ASSOCIATE MEMBERS. *THE INSTITUTIONAL FOUNDING MEMBERS ARE THE FOLLOWING RECOGNIZED ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS: (1) COLD SPRING HARBOR LABORATORY, (2) CORNELL UNIVERSITY/WEILL CORNELL MEDICINE, (3) MEMORIAL SLOAN-KETTERING CANCER CENTER, (4) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, (5) NEW YORK-PRESBYTERIAN HOSPITAL, (6) NEW YORK UNIVERSITY, SCHOOL OF MEDICINE, (7) NORTHWELL HEALTH, (8) THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, ON BEHALF OF STONY BROOK UNIVERSITY, (9) THE ROCKEFELLER UNIVERSITY, (10) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, AND (11) ALBERT EINSTEIN COLLEGE OF MEDICINE. *ASSOCIATE MEMBERS: (1) AMERICAN MUSEUM OF NATURAL HISTORY, (2) HOSPITAL FOR SPECIAL SURGERY, (3) THE NEW YORK STEM CELL FOUNDATION, (4) HACKENSACK MERIDIAN HEALTH, (5) GEORGETOWN LOMBARDI COMPREHENSIVE CANCER CENTER, AND (6) RUTGERS CANCER INSTITUTE OF NEW JERSEY. FORM 990, PART VI, SECTION A, LINE 7A ORGANIZATION MEMBERS - DECISION MAKING EACH INSTITUTIONAL FOUNDING MEMBER APPOINTS ONE REPRESENTATIVE TO SERVE ON NYGC'S BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES THE SCIENTIFIC DIRECTOR AND OTHER DESIGNATED DIRECTORS OR INDIVIDUALS APPOINTED BY THE BOARD. DECISIONS REQUIRING BOARD APPROVAL INCLUDE THE ADMISSION OF NEW MEMBERS, CHANGES TO THE MISSION, CERTIFICATE OF INCORPORATION, AND BYLAWS, APPOINTMENT OR REMOVAL OF THE CHAIRPERSON OF THE BOARD AND THE SCIENTIFIC DIRECTOR, AND ADOPTION OF CERTAIN POLICIES AND PROCEDURES. THE BOARD ALSO REVIEWS AND APPROVES THE ANNUAL OPERATING BUDGET. MANAGEMENT HAS THE ABILITY TO ENTER INTO BUSINESS ARRANGEMENTS AND CONTRACTS, INCLUDING FINANCING ARRANGEMENTS AND HAS THE DISCRETION TO MAKE CERTAIN DECISIONS WITHOUT FORMAL BOARD APPROVAL. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW THE FORM 990 IS PREPARED BY AN INDEPENDENT PUBLIC ACCOUNTING FIRM, UTILIZING INFORMATION PROVIDED BY MANAGEMENT. UPON RECEIPT OF THE DRAFT FORM 990, MANAGEMENT, INCLUDING THE CHIEF FINANCIAL OFFICER; DIRECTOR OF FINANCE; GENERAL COUNSEL; AND THE SCIENTIFIC DIRECTOR/CEO REVIEW THE FORM. PRIOR TO FILING, MANAGEMENT PRESENTS THE FORM 990 TO THE AUDIT COMMITTEE OF THE BOARD FOR REVIEW AND COMMENT. ALSO PRIOR TO FILING, MANAGEMENT PROVIDES THE FORM 990 TO THE ENTIRE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY & REVIEW NYGC REQUIRES ALL INTERESTED PERSONS (DEFINED AS BOARD MEMBERS, OFFICERS, AND KEY EMPLOYEES) TO DISCLOSE CONFLICTS OF INTEREST AS REQUIRED BY THE CONFLICT OF INTEREST POLICY. NYGC FOLLOWS A PROCEDURE FOR OBTAINING SUCH DISCLOSURES ANNUALLY. ANY POTENTIAL CONFLICTS OF INTEREST DISCLOSED BY BOARD MEMBERS OR OFFICERS MUST BE REVIEWED BY THE BOARD. IF AN INTERESTED PERSON HAS A POTENTIAL CONFLICT OF INTEREST, HE OR SHE MAY PRESENT INFORMATION RELEVANT TO THE CONFLICT OF INTEREST OR UNDERLYING TRANSACTION AT A BOARD OR COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT THAT CREATES THE POTENTIAL CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION REVIEW AND APPROVAL FOR THE ORGANIZATION'S TOP MANAGEMENT OFFICIAL, PLEASE REFER TO SCHEDULE J NARRATIVES FOR THE PROCESS OF DETERMINING COMPENSATION. FOR 2022, NYGC HIRED AN INDEPENDENT, OUTSIDE COMPENSATION CONSULTANT TO PERFORM AN ANALYSIS OF SENIOR MANAGEMENT'S TOTAL COMPENSATION. THE REVIEW SHOWED THAT THE COMPENSATION PAID TO MEMBERS OF SENIOR MANAGEMENT WAS REASONABLE. THE COMPENSATION COMMITTEE OF THE BOARD (WHICH IS COMPOSED OF INDEPENDENT BOARD MEMBERS) MET AT A COMMITTEE MEETING HELD IN FEBRUARY 2022 AND APPROVED THE 2022 COMPENSATION TO BE PAID TO SENIOR MANAGEMENT. THE COMMITTEE DOCUMENTED ITS ACTIONS IN WRITTEN MEETING MINUTES. THE SENIOR MANAGEMENT TEAM RECEIVED STANDARD MERIT INCREASES IN 2022. FORM 990, PART VI, SECTION C, LINE 19 NYGC'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART VII, SECTION A IN 2022, TOM MANIATIS, PHD., SCIENTIFIC DIRECTOR & CEO, WAS EMPLOYED BY AN UNRELATED ENTITY AND LEASED TO NYGC TO DEVOTE 80% OF HIS TIME AND EFFORT TO SERVING AS NYGC'S SCIENTIFIC DIRECTOR AND CEO, AN OFFICER OF THE CORPORATION, AND AN ASSOCIATE MEMBER OF NYGC'S FACULTY, WITH RESPONSIBILITY FOR OVERSEEING NYGC'S RESEARCH PROGRAMS AND FOR UNDERTAKING SUCH OTHER ACTIVITIES AS NYGC'S BOARD OF DIRECTORS REQUESTED FROM TIME TO TIME. DR. MANIATIS DEVOTES 20% OF HIS TIME TO HIS DUTIES AT THE UNRELATED ENTITY, WHERE HE MAINTAINS A LABORATORY AND CONDUCTS INDEPENDENT, INVESTIGATOR-INITIATED RESEARCH PROJECTS.